# CICC Healthcare Investment Fund

> CICC Healthcare Investment Fund is a VC fund backing Health Care. See 10 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Beijing, China
- Total investments: 10
- Last investment: Jun 2022
- Lead investor: 50%
- Last updated: Aug 2026

CICC Healthcare Investment Fund is a healthcare investment vehicle of China’s CICC Capital.

## Contacts

5 contacts available for CICC Healthcare Investment Fund. Shizune tracks 1 team members at CICC Healthcare Investment Fund. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/cicc-healthcare-investment-fund?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 5 | 50% |
| Biotechnology | 4 | 40% |
| Health Diagnostics | 3 | 30% |
| Medical | 2 | 20% |
| Biopharma | 2 | 20% |

17 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 3 | 30% |
| Venture - Series Unknown | 3 | 30% |
| Series A | 1 | 10% |
| Series C | 1 | 10% |
| Series D | 1 | 10% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 7 | 70% |
| Israel | 1 | 10% |
| United States | 1 | 10% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Huang Zhaohui | Managing Director | 0 | https://shizune.co/investors/profile/huang-zhaohui-a988 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| NuProbe | An early stage molecular diagnostics company. | $50M | Series B | Jun 02, 2022 |  |
| NuProbe | An early stage molecular diagnostics company. | $50M | Series B | Jun 02, 2022 |  |
| Gloria spectrum | Gloria spectrum offers mass spectrometry applications as its core technology as well as multi-omics data-driven product innovation strategy. |  | Venture - Series Unknown | May 05, 2022 |  |
| Tianbing Technology | Tianbing Technology is an advanced aerospace propulsion system supplier and aerospace vehicle provider. Tianbing Technology independently develops the next-generation ambient temperature green HCP liquid propellant and minimalist aerospace propulsion system. As an upgraded product of traditional chemical propulsion system, it can meetcost-effective aerospace. Advance system supporting needs. The next-generation green HCP aerospace propulsion system, first tested by Tianbing Technology, can be used in the small-vehicle main power and launch vehicle upper-level propulsion system. | $15.7M | Series B | Feb 09, 2022 |  |
| Chemsemi | ChemSemi develops 5G chips and semiconductor technologies. | $157.8M | Series A | Jan 21, 2022 |  |
| MicroPort NeuroTech | MicroPort NeuroTech is a medical device company that specializes in neurological intervention. It develops innovative products that deliver safe, effective, and accurate solutions for patients with cerebrovascular diseases.MicroPort NeuroTech's unique products include WILLIS Intracranial Stent Graft System, APOLLO Intracranial Stent System,and Tubridge Vascular Reconstruction Device for treatments. The products promote therapeutic options adapted to specific needs. MicroPort NeuroTech was founded on May 2012 and is based in Shanghai, China. | $150M | Venture - Series Unknown | Nov 12, 2021 |  |
| Changmugu Medical | Changmugu Medicalis an artificial intelligence (AI)-powered healthcare start-up providing AI-powered surgical robot solutions. | $84.5M | Series B | Nov 10, 2021 |  |
| Thousand Oaks Biopharmaceuticals | Thousand Oaks Biopharmaceuticals is a developer of biopharmaceutical technologies intended to produce protein and vaccine compounds. The company's technologies provide integrated control solutions, including the use of technical expertise to optimize the process and increase protein expression to reduce production scale, providingbio-pharmaceutical companies with personalized, chemical-defined cell culture media, formula production, technical support and ancillary services. | $61.5M | Series C | Mar 10, 2021 |  |
| MitrAssist | MitrAssist introduces a minimally invasive approach to MR treatment. Its mitral valve implant works in unison with the natural mitral valve without harming its functionality.MitrAssist has developed a new approach to treating MR that is neither repair nor replacement. Instead, its proprietary valve implant is placed on top of the natural valveto work in unison with it and to enhance valve functionality.MitrAssist’s “valve-in-valve” approach overcomes the various challenges of MR and offers an improved treatment solution for all MR patients. It has significant advantages over minimally invasive solutions – both existing and in development. | $50M | Venture - Series Unknown | Dec 03, 2020 |  |
| Genetron Health | Genetron Health is a world-leading expert in precision medicine.They are committed to developing health management products that cover all elements of full-cycle cancer clinical treatment (including risk assessment, early screening, molecular pathology diagnosis, medication guidance and prognosis monitoring) and effectively applying genomic data toassist medical experts and research scientists. Additionally, they provide cancer patients and high-risk and healthy individuals with reliable molecular clinical services and professional cancer genetic risk assessment.In just three years, Genetron Health has built global genomics sequencing and bioinformatics platforms, established two research and development centers in both North Carolina, U.S., and Beijing, China, and set up clinical laboratories in Beijing, Shanghai, Hangzhou and Chongqing of over 10,000 square meters.In the future, Genetron Health will spread its sales network throughout China with professional marketing, product management, medical experts and scientific research teams, and will provide service for Chinese and global cancer patients with its strong foundation in cancer genomics and efficient clinical translation. | $71M | Series D | Nov 21, 2019 |  |

10 of 10 investments shown.

## Co-investors
- [BioTrack Capital](https://shizune.co/investors/profile/biotrack-capital) — VC Fund, 2 deals together
- [CDH Investments](https://shizune.co/investors/profile/cdh-investments) — VC Fund, 2 deals together
- [CR-CP Life Science Fund](https://shizune.co/investors/profile/cr-cp-life-science-fund) — VC Fund, 2 deals together
- [Deguan Capital](https://shizune.co/investors/profile/deguan-capital) — VC Fund, 2 deals together
- [Haoreng Capital](https://shizune.co/investors/profile/haoreng-capital) — VC Fund, 2 deals together
- [HSG](https://shizune.co/investors/profile/hsg-cap) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does CICC Healthcare Investment Fund invest in?

CICC Healthcare Investment Fund invests primarily in Health Care, Biotechnology and Health Diagnostics startups, most often at Series B and Venture - Series Unknown stage. Most of the 10 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact CICC Healthcare Investment Fund?

For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at CICC Healthcare Investment Fund?

The team at CICC Healthcare Investment Fund includes Huang Zhaohui (Managing Director). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co